Patient/advocate, Diane Redington, and Dr. Michael Birrer discuss the results of GCS Project research to-date and where the research is headed. This is part one of a nine-part series.
Dr. Birrer states that they have already had initial results. They are doing what Dr. Birrer calls a “molecular deep dive”—a technically sophisticated analysis—on a fairly large set of tumors. They have been able to characterize some mutational events that occur in GYN Carcinosarcoma, coming from both the ovary and from the uterus. Some events are what Dr. Birrer calls ‘targetable,’ meaning that they can be treated.
Read the video transcript: Click here